Efficacy, safety and pharmacology of oral ASN002, a novel Jak/Syk inhibitor, in moderate-to-severe atopic dermatitis: A randomized, double-blind, placebo-controlled study

Authors
Category Primary study
ConferenceBritish Journal of Dermatology
Year 2018
This article has no abstract
Epistemonikos ID: 4ca9adbb27c6e446b4f300b2f42d510ea6a51673
First added on: Apr 29, 2026